Explore a selection of peer-reviewed publications highlighting the scientific achievements and collaborative research efforts of CD3 and its partners. A complete overview of all CD3 publications can be found here.
Publications
Protein aggregation inhibitors induce divergent transcriptional responses in a cellular model of ɑ-synuclein seeded aggregation.
Van Minsel P, et al. – npj Parkinson’s Disease, 2026
A coronavirus assembly inhibitor that targets the viral membrane protein.
Laporte M, et al. – Nature, 2025
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H, et al. – Mol Cancer Ther, 2024
Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Goethals O, et al. – Nature, 2023
Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model.
Van Loy T, et al. – Cell Mol Life Sci, 2022
A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.
Kaptein SJF, et al. – Nature, 2021
Functional expression and pharmacological modulation of TRPM3 in human sensory neurons.
Vangeel L, et al. – Br J Pharmacol, 2020
Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release.
Held K, et al. – Proc Natl Acad Sci U S A, 2015
Identification of novel FLT3 kinase inhibitors.
Pauwels D, et al. – Eur J Med Chem, 2013
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication.
Christ F, et al. – Nat Chem Biol, 2010